Glucotrack Closes Reverse Merger with Lokahi Therapeutics, Secures $4.45M Bridge Financing and $50M ELOC
GCTK sits 96% above its 52-week low of $0.291 on elevated volume (11× avg).
Summary
Glucotrack closed a reverse merger with Lokahi Therapeutics, handing Lokahi 90% control. The deal includes $4.45M in bridge financing with toxic terms and a $50M equity line of credit, aimed at staving off delisting and addressing going concern risks.
Key Events · M&A and Partnerships · GCTK
-
Reverse Merger Closed
Glucotrack completed a reverse merger with Lokahi Therapeutics on July 14, 2026. Lokahi securityholders received 90% control of the combined company via common and convertible preferred stock, leaving existing Glucotrack shareholders with 10%.
-
Bridge Financing Secured
The company raised $4.45 million through senior secured convertible notes with a 22% original issue discount, 8% interest, and 9-month maturity. The notes are convertible at a discount to market, and warrants provide 125% coverage.
-
$50M Equity Line of Credit Established
Glucotrack entered a $50 million common stock purchase agreement with White Lion Capital, allowing the company to sell shares at a discount over three years. The investor also received a $10 million commitment warrant and $1 million in commitment shares.
-
Management Overhaul
Erik Emerson was appointed CEO and board member, replacing Paul V. Goode as CEO. Goode will serve as CTO of the combined company and CEO of the CBGM subsidiary.
Analysis · GCTK · Industrial Applications And Services
Glucotrack completed a reverse merger with Lokahi Therapeutics, giving Lokahi 90% control of the combined company. The deal includes a $4.45 million bridge loan with toxic terms — 22% original issue discount, 8% interest, and warrants with 125% coverage — and a $50 million equity line of credit that allows the investor to buy shares at a discount. The merger is a last-ditch effort to avoid Nasdaq delisting and address the going concern warning. Existing shareholders are left with just 10% of the company, and the financing terms heavily favor the new investors, creating massive dilution risk.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCTK was trading at $0.57 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.29 to $14.14. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.